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Introduction 
Overactive bladder (OAB) is a syndrome which affects around 12% of men and women, with 
incidence increasing with age around 70-80% of people are affected by the age of 80 (1). 
Patients’ with OAB present with symptoms of urgency, increased daytime frequency and 
nocturia (2).  Around 33% of people with OAB will exhibit urinary incontinence, which 
affects women more than men. OAB has a significant negative effect on patient’s quality of 
life and can lead to social isolation and depression (3 and 1). Overactive bladder syndrome 
with urge incontinence is associated with early institutionalisation, financial cost and 
increased morbidity and mortality (4)  
Function of the Lower Urinary Tract 
The function of the lower urinary tract (LUT) is to store and intermittently release urine, and 
requires the co-ordination of smooth and striated muscles in the bladder and bladder neck, 
urethra and urethral sphincter within the bladder outlet. Coordination between these 
organs is mediated by a complex neural control system located in the brain, spinal cord and 
peripheral ganglia. The average adult bladder can hold around 350-500mls of urine. The 
sensation of bladder fullness occurs when the bladder is around half full (200mls), but 
results in no increase of pressure from the detrusor muscle until the bladders capacity is 
reached. 
Nervous control of micturition (see figure 1) 
Voluntary control of voiding requires interaction between the autonomic (mediated by the 
sympathetic and parasympathetic nerves) and somatic efferent pathways (mediated by 
pudendal nerves). When the bladder stretches during filling, the sympathetic nerves enable 
the detrusor to relax and the internal sphincter to contract. To initiate voiding, the 
parasympathetic nervous system is triggered to contract the detrusor muscle and relax and 
open the internal sphincter. The relaxation and opening of the external sphincter is under 
voluntary somatic nerve control. 
Sympathetic innervations arise in the T11-L2 region of the spinal cord and enter the base of 
the bladder and urethra via the hypogastric nerve and inferior mesenteric plexus. 
Parasympathetic innervations arise from S2-S4 spinal segments and travel in sacral roots 
and pelvic nerves to the pelvic area and bladder wall, which is where the postganglionic 
nerves supplying parasympathetic innervations to the bladder arise. Somatic nerves that 
supply the straited muscle within the external urethral sphincter arise from S2-S4 motor 
neurons and pass through the pudendal nerves (5).  
Receptors and Neurotransmitters  
Co-ordination of voiding involves four principle neuro transmitters: glutamate, serotonin, 
noradrenaline and acetylcholine. The parasympathetic neurons and somatic nerves 
primarily use acetylcholine (ACh) , while in the sympathetic neurons the neurotransmitter is 
noradrenaline.  
 Acetylcholine (ACH) is released from parasympathetic postganglionic axons in the pelvic 
nerves, which initiates bladder contraction by stimulating the M³ muscarinic receptors in the 
bladder smooth muscle. Sympathetic postganglionic neurons release noradrenaline (NA), 
which activate β³adrenergic receptors to relax the bladder smooth muscle and stimulate 
α1adrenergic receptors which contract the smooth muscle of the urethra maintaining 
closure during filling. Acetycholine is also released from somatic axons within the pudendal 
nerves, which produces contraction of the external sphincter by activating nicotinic 
cholinergic receptors. Bladder smooth muscle is also excited by ATP released from the 
parasympathetic postganglionic nerves, while nitric oxide relaxes the smooth muscle of the 
urethra. 
Glutamate is the principle neurotransmitter in the spinal cord which activates ACh release 
stimulating the nicotinic receptors in the striated urethral sphincter. This action is thought 
to be enhanced by serotonin and noradrenaline. 
There are 5 types of muscarinic acetycholine receptor (mAchR) isotopes which are 
specialised to different tissues and functions. These receptors are found in various organs 
around the body and activation can lead to various actions summarised in Table 1. The 
presence of muscarinic and nicotinic receptors in the bladder and urethra is the focus of 
pharmacological treatment options of overactive bladder 
 
 
 
 
Figure 1 Innervations of the bladder and pelvic floor 
(Bardsley, A. (2012) 'Drug Therapies for post-
menopausal urinary incontinence'. Nurse Prescribing 10 
(8), 384-391) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1 
 Innervations of the bladder and 
pelvic floor 
Stimulation of sympathetic 
neurons →relaxation detrusor 
and contraction of internal 
sphincter  
Stimulation of parasympathetic 
neurons →contracted detrusor 
Stimulation of somatic neurons 
→contraction of external 
sphincter and pelvic floor 
 
  Table 1 (6)   
Type of 
mAchR 
Organ Action 
M1 Brain, salivary glands, 
sympathetic ganglia 
Cognitive functions 
M2 Heart, Hind brain, smooth 
muscle  
Decrease in heart rate 
M3 Smooth muscle, salivary 
glands, eye  
Smooth muscle contraction 
Salivary secretion 
M4 Brain Unknown but possible CNs effect  
M5 Brain, Eye  Unknown but possible CNs effects  
 
Overactive Bladder and Urge Incontinence 
When a bladder becomes overactive there are involuntary contractions of the bladder wall 
during the filling phase of micturition. For some people an overactive bladder is idiopathic, 
however for many the cause is related to a known neurogenic condition such as multiple 
sclerosis.  The symptom of an urgent, sudden and compelling need to void is the most 
bothersome and usually drives the other symptoms of OAB.Urgency urinary incontinence is 
defined as the complaint of involuntary leakage of urine accompanied by or preceded by the 
urgent need to void (7,4). Frequency denotes the need to void too often during waking 
hours, and is usually defined as more than 8 times in 24hours. However the ICS do not asign 
a particular figure as increases in daytime frequency can be subjective and a bladder voiding 
diary should be maintained to confirm (7).  
Assessment  
The clinical diagnosis of OAB is based on an holistic history, which must include a baseline 
frequency volume chart. Baseline charts should be completed for a minimum of 3 days, 
covering work and leisure time (8).  A urinaylsis should be undertaken to rule out infection 
and if blood is present in the urine culture, patients should be investigated for bladder 
cancer. Post void residual urine volume should be assessed using a bladder scan (8). 
Significant post void residual urine can lead to symptoms of urgency and frequency and is a 
particular issue for those patients with an underlying neurogenic condition. Urodynamic 
assessment is not required prior to commencing conservative treatment.  
Treatment options 
Lifestyle interventions, behavioural therapy and pharmacotherapy are the main first line 
options for treating OAB and include establishing normal voiding patterns, reducing bladder 
irritants such as caffeine, management of fluid intake, weight control, regularising bowel 
habits and smoking cessation (9). Combining behavioural modifications with 
pharmacotherapy is shown to enhance the effectiveness (10, 4).  
Pharmacotherapy 
The updated NICE guidelines (8): Urinary Incontinence: the management of urinary 
incontinence in women recommend that before patients are started on medication for OAB 
the following should be discussed  
 The likelihood of success and associated common adverse effects   
 The frequency and route of administration 
 That some adverse effects such as dry mouth and constipation may indicate that 
treatment has starting to have an effect 
 That they may not see  the full benefits until they have been taking the treatment for 
4 weeks 
 
The following anticholinergic medicines are currently available in the UK. 
 Darifenacin  
 Oxybutynin – available in immediate release, extended release, transdermal and   
     topical gel formats    
 Tolterodine – available in immediate release and extended release formulations 
 Trospium – available in immediate and extended release formulations 
 Propiverine - available in immediate and extended release formulations 
 Solifenacin 
 Fesoterodine 
 
When choosing a drug for the treatment of OAB, NICE (8) recommend starting with 
oxybutinin (immediate release), tolteradine (immediate release) or darifenacin (once daily 
preparation). However oxybutinin should not be offered to frail older patients due to the 
risk of adverse effects. All patients should be reviewed at 4 weeks following the start of 
treatment and if the first line treatment is ineffective or not well tolerated a higher dose or 
an alternative drug should be offered, having considered the most cost-effective alternative. 
Referral to a multi-disciplinary secondary care team should only be made if drug treatment 
is unsuccessful or the patient wishes to discuss alternative options. 
 
How do anticholinergic medications work? 
Anticholinergic medications act as agonists, inhibiting the binding of acetycholine on the 
muscarinic receptors within the detrusor muscle, which reduces the involuntary nerve 
messages that lead to uncontrolled contractions of the detrusor and increase the bladders 
ability to store urine. The action and metabolism of anticholinergic agonists varies 
depending on the affinity of an individual drug to a particular muscarinic or nicotinic 
receptor within the detrusor.  Anticholinergic medications are also used to reduce OAB 
associated nocturia. 
Precautions in prescribing anticholinergic medications 
As anticholinergic medications target M receptors, they are associated with  a number of 
side effects including constipation, dry mouth, blurred vision and somnolence, with more 
serious events including  cognitive and cardiac side effects, as these receptors are present 
elsewhere within the body (see table 1)  (11).  For older people there may be central 
nervous system (CNS) effects, for example cognitive disturbances which range from 
sedation, inability to concentrate, memory impairment and delirium.  This high side effect 
profile is associated with poor concordance, with a reported 43-83% discontinuation rate 
and over half of patients never refilling the initial prescription (12).  
When considering using anticholinergic medications for the treatment of OAB, the 
prescriber must consider coexisting conditions, for example poor bladder emptying. 
Anticholinergic medications are metabolised by the liver and excreted through the kidneys, 
so care should be taken in patients with renal and hepatic impairment. Concomitant use of 
other medications with anticholinergic effects such as antihistamines may also increase the 
risk of adverse effects (11). Low doses should always be prescribed initially to minimise the 
adverse effects (8).  
 
Oestrogens 
Muscle mass generally decreases with age. The urethral mucosa forms a watertight seal 
aiding continence and evidence suggests that the urethra is hormonally sensitive with 
oestrogen having an advantageous effect (13). However the role of oestrogen replacement 
in treating incontinence associated with OAB is unclear (8). Systemic oestrogens are 
associated with an increased risk of systemic adverse effects for example thromboembolism 
(8). Following a review of the current available evidence NICE (8) recommend that systemic 
oestrogen (hormone replacement therapy) should not be offered for the treatment of 
urinary incontinence, but intravaginal oestrogen can aid post menopausal women with 
vaginal atrophy (13).    
Botulinum toxin 
Botulinum toxin (type A) is a neurotoxin, derived from the bacteria Clostridium botulinum.  
One action of Botulinum toxin is to inhibit the release of acetycholine from the pre-synaptic 
cholinergic nerve endings, which temporarily paralysis the muscle into which it is injected, 
leading to decreased muscle contractibility (1). The toxin is injected directly into the 
detrusor muscle under cystopic guidance, and can be repeated every 6-12months. NICE (8) 
recommend the use of botulinum toxin A with OAB when patients have not responded to 
other conservative treatment options and the patient has been reviewed by a 
multidisciplinary team (MDT). Patients must be counselled prior to treatment on the risks 
and benefits, which include the absence of evidence on the duration of effects and the long 
term efficacy and risks (8). One of the main adverse effects of injecting botulinum toxin A 
into the bladder is that it can cause paralysis of the detrusor muscle leading to large residual 
urines as the bladder is unable to empty fully. Therefore all women who are offered Botox 
injections must be willing and able to undertake self catheterisation prior to the procedure 
(8).   
Where OAB sypmtoms do not respond to conservative and pharmacological options or 
injection of botulinum toxin, or where patients areunable to perfrom intermittent self 
cathetrisation, percutaneous sacral nerve stimulation (P-SNS) can be offered (8). The 
principle of neurostimulation is that exciting the sacral reflex pathway at the S3 nerve root 
will inhibit the reflex behaviour of the bladder and so reduce detrusor overactivity.  
Conclusion 
Incontinence associated with overactive bladder syndrome is common and can affect the 
physical, psychological and social well being of individuals. Alongside lifestyle and 
behavioural modifications, the main treatment option is pharmacological. The revised NICE 
guidelines provide recommendations for the use of pharmacological treatment. 
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